Your Health, We Care
Concomitant administration of strong CYP2C8 inhibitors (e.g., gemfibrozil) with Daprodustat is contraindicated due to a marked increase in daprodustat exposure.
Concomitant administration of moderate CYP2C8 inhibitors (e.g., clopidogrel) increases daprodustat exposure. Reduce the starting dose of Daprodustat by half when initiating treatment in patients on clopidogrel or a moderate CYP2C8 inhibitor except in patients whose starting dose is already 1 mg. Monitor hemoglobin and adjust the dose of Daprodustat when initiating or stopping therapy with clopidogrel or a moderate CYP2C8 inhibitor during treatment with Daprodustat.
CYP2C8 inducers (e.g., rifampin) may decrease daprodustat exposure, which may result in loss of efficacy. Monitor hemoglobin and adjust the dose of Daprodustat when initiating or stopping therapy with CYP2C8 inducers during treatment with Daprodustat.
from FDA，2023.02
